MUC15 and hepatocellular carcinoma: Therefore, it is advisable to evaluate MUC15 expression in HCC tumors to identify patients who might benefit from lenvatinib therapy before deciding on a course of treatment, which merits further investigation in biomarker-guided clinical trials.